Processing...
Clinical Trials for Kidney Cancer
Search
Search
There are 123 active trials for advanced/metastatic kidney cancer.
Click on a trial to see more information.
123 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with advanced unresectable or metastatic solid tumors (including a broad range such as ovarian, pancreatic, GI, lung, and more) or relapsed/refractory multiple myeloma who have failed or are intolerant to standard therapies are eligible to receive QXL138AM, a masked anti-CD138 immunocytokine fused to interferon alpha-2a designed for tumor-targeted immune activation.
ClinicalTrials.gov ID: NCT06582017
TrialFetch AI summary: This trial enrolls adults with metastatic or unresectable CD70-expressing cancers (including clear cell renal cell carcinoma and other solid tumors) who have progressed after at least one prior therapy, to receive a lymphodepleting regimen followed by infusion of autologous T cells genetically engineered with an anti-CD70 chimeric antigen receptor targeting CD70-positive tumor cells, plus high-dose aldesleukin (IL-2) post-infusion.
ClinicalTrials.gov ID: NCT02830724
TrialFetch AI summary: Enrolling adults with advanced/metastatic solid tumors lacking standard options; dose-escalation all-comers followed by expansion in biomarker-selected cohorts including NSCLC with YES1 or TYMS amplification or FAT1 mutation, renal cancer or mesothelioma with NF2 mutation, and other tumors with NF2/FAT1/LATS1 mutations or TYMS/YAP1/YES1/TAZ1 amplifications. Treatment is NXP900, an oral conformation-selective SRC family kinase inhibitor with high potency against YES1/SRC, given as monotherapy.
ClinicalTrials.gov ID: NCT05873686
TrialFetch AI summary: Adults with locally advanced/metastatic c‑Kit–expressing solid tumors (including GIST, SCLC, adenoid cystic carcinoma, uveal melanoma, NETs, chromophobe or clear‑cell RCC) who have progressed after or are ineligible/intolerant to standard therapy receive NN3201, an IV c‑Kit (CD117)–targeted antibody‑drug conjugate delivering MMAE every 3 weeks. Expansion cohorts include GIST (post‑imatinib), SCLC, and other c‑Kit–positive tumors to assess safety and preliminary efficacy.
ClinicalTrials.gov ID: NCT06805825
TrialFetch AI summary: Adults and adolescents (16–80 years) with CD70-positive advanced clear cell RCC (post PD-1/PD-L1 and anti-angiogenic therapy), mesothelioma (progressive after standard options including checkpoint blockade), or osteosarcoma (recurrent/refractory after anthracycline) receive fludarabine/cyclophosphamide lymphodepletion followed by a single infusion of allogeneic cord blood–derived CAR NK cells targeting CD70 via a CD27-based CAR, armored with IL-15 for persistence and containing an inducible caspase-9 safety switch. Single-arm dose-escalation/expansion evaluates safety, dose, persistence, and preliminary activity.
ClinicalTrials.gov ID: NCT05703854
TrialFetch AI summary: Adults with relapsed/refractory GPC3-positive solid tumors (including HCC meeting BCLC A–C and Child-Pugh <7) receive lymphodepleting cyclophosphamide/fludarabine followed by a single infusion of autologous GPC3-targeted CAR T cells engineered to express IL-15 for enhanced persistence and an inducible caspase-9 safety switch. Key exclusions include prior organ transplant, uncontrolled infection, HIV, pregnancy, high-dose steroids at infusion, and murine protein hypersensitivity/HAMA.
ClinicalTrials.gov ID: NCT05103631
TrialFetch AI summary: Enrolling adults with metastatic rare genitourinary cancers across multiple histologic cohorts (e.g., small cell/neuroendocrine bladder, variant urothelial, penile, sarcomatoid/unclassified RCC, collecting duct, renal medullary, urethral; including a bone-only GU cohort), with up to two prior lines allowed (cohort-specific exceptions. Patients receive cabozantinib (MET/VEGFR2/AXL multi-kinase inhibitor) plus nivolumab (PD-1) and ipilimumab (CTLA-4) for up to 2 years.
ClinicalTrials.gov ID: NCT03866382
TrialFetch AI summary: Adults with advanced or metastatic renal cell carcinoma, urothelial carcinoma, or castration-resistant prostate cancer receive oral DCC-2812 monotherapy, a first-in-human, selective GCN2 activator that engages the integrated stress response (eIF2α phosphorylation/ATF4) to disrupt tumor survival pathways. Dose-escalation evaluates safety, dose-limiting toxicities, and PK, with preliminary antitumor activity assessed.
ClinicalTrials.gov ID: NCT06966024
TrialFetch AI summary: Adults with locally advanced or metastatic clear cell RCC (any VHL status) receive oral HC-7366—an activator of the GCN2 integrated stress response pathway—either alone or combined with belzutifan (HIF-2α inhibitor), with combination dose escalation/expansion to define MTD/RP2D. Suitable for patients needing a belzutifan-based regimen or eligible for first- or later-line investigational therapy in ccRCC.
ClinicalTrials.gov ID: NCT06234605
TrialFetch AI summary: Adults with advanced, HLA‑G–positive solid tumors (ECOG 0–1) after standard therapies receive leukapheresis, fludarabine/cyclophosphamide lymphodepletion, then a single infusion of IVS‑3001, an autologous third‑generation CAR‑T targeting HLA‑G (an immune checkpoint ligand for ILT2/ILT4). Phase 2a includes cohorts for clear cell RCC post‑CPI/TKI, epithelial ovarian cancer post‑platinum (± prior PARP if BRCA1/2‑mutant), and other HLA‑G+ tumors without standard options.
ClinicalTrials.gov ID: NCT05672459